LIFECORE BIOMEDICAL INC DE
For the period ended May 28, 2023. Filed Jul 19, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 28, 2023 · Filed Jul 19, 2024
Contents
Performance Goals
In fiscal year 2023, performance measures were broken into two categories:
Adjusted EBITDA of $38.805 million with Adjusted EBITDA performance weighted 75% and revenue goal of $128.1 million, with revenue performance weighted 25%. Adjusted EBITDA is defined as EBITDA, excluding restructuring charges, other non-recurring charges, and management fees, and including the cost of bonuses.
| 75% Weighting EBITDA Portion of Bonus · + · 25% Weighting Revenue Portion of Bonus | |||||||
|---|---|---|---|---|---|---|---|
| ($000s) · % of · % EBITDA · ($000s) · % of · % Revenue | |||||||
| FY23 · EBITDA · Target · FY23 · Revenue · Target | |||||||
| EBITDA · Goal · Earned · Revenue · Goal · Earned | |||||||
| Cap | $50,447 | 130% | 175% | Cap | $147,315 | 115% | 115% |
| Goal | $38,805 | 100% | 100% | Goal | $128,100 | 100% | 100% |
| Threshold | $33,413 | 86% | —% | Threshold | $115,290 | 90% | 90% |
| Interpolation used if performance is between points shown. | |||||||
| EBITDA threshold must be met for any bonus to be earned. | |||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.